Physician profile
Robin M Wind
NPI 1265427546
$778.55
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2020: $122 · 2022: $106 · 2023: $58.60 · 2024: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $223.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $128.67 | 2019-2024 | |
| Lilly USA, LLC | $119.93 | 2024 | Zepbound |
| Sanofi Pasteur INC. | $61.45 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.37 | 2019 | |
| Currax Pharmaceuticals LLC | $53.26 | 2020 | |
| Eisai INC. | $52.48 | 2019 | |
| Glaxosmithkline, LLC. | $45.72 | 2022-2023 | Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $42.88 | 2019-2020 | |
| Abbvie INC. | $39.12 | 2022 | |
| Genentech USA, INC. | $36.11 | 2019 | |
| Novo Nordisk INC | $34.88 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.67 | 2020 | |
| Amgen INC. | $18.13 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $17.62 | 2019 | |
| Inspire Medical Systems, INC. | $13.22 | 2024 | Inspire |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $12.13 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $11.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Wind listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.